ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
alxo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ALX Oncology Holdings Inc. (ALXO) measures how much investors pay for each dollar of the company's trailing earnings. ALXO's current PE ratio of N/A is calculated by dividing its stock price of $1.59 by its TTM earnings per share of -$1.64.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ALX Oncology Holdings Inc.You ALXO | $214M | N/A | — | -$1.64 |
 Adverum Biotechnologies, Inc. ADVM | $96M | N/A | — | -$6.62 |
 Artiva Biotherapeutics, Inc. ARTV | $176M | N/A | — | -$3.43 |
 aTyr Pharma, Inc. ATYR | $46M | N/A | — | -$0.80 |
 Biomea Fusion, Inc. BMEA | $71M | N/A | — | -$1.18 |
 Precision BioSciences, Inc. DTIL | $88M | N/A | — | -$3.63 |
 Fractyl Health, Inc. Common Stock GUTS | $51M | N/A | — | -$1.86 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.90 | — | |
2024-12-31 FY2024 | — | $-2.58 | — | |
2023-12-31 FY2023 | — | $-3.74 | — | |
2022-12-31 FY2022 | — | $-3.03 | — | |
2021-12-31 FY2021 | — | $-2.07 | — | |
2020-12-31 FY2020 | — | $-1.15 | — | |
2019-12-31 FY2019 | — | $-0.88 | — | |
2018-12-31 FY2018 | — | $-0.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ALX Oncology Holdings Inc. (ALXO) measures how much investors pay for each dollar of the company's trailing earnings. ALXO's current PE ratio of N/A is calculated by dividing its stock price of $1.59 by its TTM earnings per share of -$1.64.
Frequently asked questions
ALXO pe ratio · 6 questionsALXO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.59 and TTM EPS of -$1.64. Data sourced from Financial Modeling Prep via ALXO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ALX Oncology Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09